1122P An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients

Abstract

CHRYSALIS is an open-label, single arm phase 1b/2 clinical trial conducted to assess safety and efficacy of amivantamab in patients with EGFR Ex20ins advanced NSCLC, after progressing on platinum doublet chemotherapy (CT). In absence of a comparator arm in CHRYSALIS, comparison of trial outcomes versus an external cohort of similar patients allows to quantify clinical benefits relative to treatments used in current clinical practice.